Maris 2023: Peter MacCallum Cibiyar Ciwon daji (Peter Mac) a Ostiraliya da Cartherics Pty Ltd sun shiga yarjejeniyar ci gaba na haɗin gwiwa (CDPA) don haɓaka CTH-002 don maganin ciwon daji na ovarian.
Gwajin asibiti da Peter Mac zai gudanar zai zama karo na farko da aka gwada samfurin maganin tantanin halitta na CAR-T wanda ke ɗauke da gyare-gyaren kwayoyin halitta da aka haɗa cikin CTH-004 a cikin mutane.
Ciwon daji na Ovarian shine mafi munin ciwon daji na mata a Ostiraliya, yana ɗaukar rayuka sama da 1,000 kowace shekara. Tare da adadin tsira na shekaru biyar na 49% kawai, akwai buƙatar gaggawa don bincike don ba waɗanda aka gano mafi kyawun damar rayuwa.
Simon Harrison, darektan Cibiyar Kwarewa a cikin Salon salula immunotherapy a Peter Mac, ya ce: "CAR-T-cell far ne mai ƙarfi immunotherapy wanda aka keɓance musamman ga kowane majiyyaci kuma wanda ke sake manufar T-cell nasu don yaƙar kansa.
“It has emerged as a new treatment paradigm in cutar kansa where it can produce complete responses, meaning their blood cancer has disappeared, in patients who have exhausted all other treatment options. The Centre of Excellence in Cellular Immunotherapy at Peter Mac is part of an international effort to expand CAR T-cell far fiye da ciwon daji na jini, kuma muna farin cikin yin haɗin gwiwa tare da Cartherics akan wannan gwajin asibiti na farko na ɗan adam don ciwon daji na ovarian.
Alan Trounson, CEO of Cartherics, said: “There are many patients needing help to control ciwon daji na ovarian and CAR-T therapy could be a game changer for them. It is our priority to ensure this potential therapy is tested in gwaji na asibiti da wuri-wuri."
Cartherics board advisor, Heather Hawkins said: “As an ovarian mai tsira da ciwon daji and patient advocate, I am truly grateful for the vision, skill and dedication of the Cartherics team who are working tirelessly – seeking to improve the survival rates and the quality of life of women diagnosed with ovarian cancer. This announcement brings a real sense of progress and hope in this space.”
Fiye da kashi 80 cikin XNUMX na masu ciwon daji na ovarian waɗanda suka fara yin nasara a aikin tiyata da jiyya suna sake dawowa.
Manufofin farko na binciken haɗin gwiwar shine samar da CTH-004 a ma'auni na asibiti da kuma gudanar da gwaji na asibiti na lokaci na. Cibiyar Kwarewa ta Kwarewa a cikin Immunotherapy ta Peter Mac ce za ta jagoranci wannan shirin, yayin da abokan aikin Peter Mac za su gudanar da masana'antu, Cell Therapies Pty Ltd.
Gwajin asibiti da farko za ta yi rajistar marasa lafiya shida zuwa goma sha biyu masu fama da ciwon daji na ovarian waɗanda kafin maganin chemotherapy ya gaza. Manufar farko na wannan gwaji na asibiti shine don tantance amincin CTH-004 a cikin wannan yawan masu haƙuri.
Cartherics da Peter Mac kwanan nan sun sanar da haɗin gwiwa don CTH-001, wani samfurin CAR-T mai sarrafa kansa wanda Cartherics ya haɓaka. Masu haɗin gwiwar sun yarda, bisa la'akari da cikakkun bayanai, cewa Peter Mac zai mayar da hankalinsa akan CTH-004.
Game da ciwon daji na kwai
Ovarian cancer is a disease in which abnormal cell growth in one or both ovaries leads to the development of cancer. Approximately 314,000 new ovarian cancer cases and 207,000 deaths occurred globally in 2020.
A farkon matakansa, ciwon daji na ovarian yawanci asymptomatic ne kuma akai-akai ana gano shi a ƙarshen mataki. Tiyata da chemotherapy sune mafi yawan jiyya, ko dai kawai ko a hade. Fiye da kashi 80 cikin XNUMX na masu ciwon daji na ovarian waɗanda suka fara yin nasara a aikin tiyata da jiyya suna sake dawowa.
Game da Peter MacCallum Cancer Center
Cibiyar Ciwon daji ta Peter MacCallum cibiyar bincike ce ta duniya, ilimi, da wurin jiyya, da kuma sabis na kiwon lafiyar jama'a kawai na Ostiraliya wanda ke keɓe keɓancewar kula da kansa. Cibiyar tana daukar ma'aikata 3,300, ciki har da masu bincike sama da 750 na dakin gwaje-gwaje da na asibiti, wadanda dukkansu sun sadaukar da kansu don samar da ingantattun magungunan cutar kansa, kulawa, da kuma hanyoyin da za a iya magance su.
Cibiyar da kyau a cikin ƙwaƙwalwar ƙwaƙwalwar ajiya ta Peter Mac, da ke haɓaka, abokan masana'antar Pty Ltd, don kunna amfani da waɗannan samfuran sel a cikin gwaji na asibiti don cutar masu cutar kansa don cutar kansa.
Bugu da ƙari, kamfanin yana ƙirƙirar autologous CAR-T hanyoyin kwantar da hankali. Waɗannan suna amfani da ƙwayoyin T da aka gyaggyara daga tsarin garkuwar marasa lafiya waɗanda ke da tasiri akan ƙwayoyin cutar kansar mai haƙuri. An samar da CTH-004 ta hanyar gyare-gyaren kwayoyin halitta ta kwayoyin T masu haƙuri don saka mai karɓa na antigen na chimeric (CAR) don ƙaddamar da alamar (TAG-72) akan ƙwayoyin ciwon daji na ovarian da kuma share kwayoyin halitta da ke cikin aikin aikin T cell.
CAR T-Cell far a China ya karu da sauri sosai, kuma a halin yanzu akwai gwaje-gwajen asibiti sama da 750 da ake gudanarwa a kasar Sin kan nau'ikan ciwon daji daban-daban.
